Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT05164263

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
  • Getz Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05164263
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Afghanistan, Kenya, Nigeria, Pakistan, Sri Lanka (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05164263. Allocation not applicable; no masking; primary purpose treatment. Start 2021-04-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
Acronym
EASE
Condition
Type II Diabetes Mellitus
Condition
Efficacy, Self
Condition
Safety Issues
Intervention (Drug)
Empagliflozin
Lead sponsor
Getz Pharma (class: industry)

Record details

Record id
cardio:ct-nct05164263
Content hash
4a6a5e18439e710d1bc40aa353124e2f3702b5cf450b800dfcea9442966e6f18